Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.

Horst D, van Leeuwen D, Croft NP, Garstka MA, Hislop AD, Kremmer E, Rickinson AB, Wiertz EJ, Ressing ME.

J Immunol. 2009 Feb 15;182(4):2313-24. doi: 10.4049/jimmunol.0803218.

2.

Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.

Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD.

PLoS Pathog. 2009 Jun;5(6):e1000490. doi: 10.1371/journal.ppat.1000490. Epub 2009 Jun 26.

3.

EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.

Horst D, Favaloro V, Vilardi F, van Leeuwen HC, Garstka MA, Hislop AD, Rabu C, Kremmer E, Rickinson AB, High S, Dobberstein B, Ressing ME, Wiertz EJ.

J Immunol. 2011 Mar 15;186(6):3594-605. doi: 10.4049/jimmunol.1002656. Epub 2011 Feb 4.

4.

Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.

Ressing ME, Keating SE, van Leeuwen D, Koppers-Lalic D, Pappworth IY, Wiertz EJ, Rowe M.

J Immunol. 2005 Jun 1;174(11):6829-38.

5.

Epstein-Barr viral BNLF2a protein hijacks the tail-anchored protein insertion machinery to block antigen processing by the transport complex TAP.

Wycisk AI, Lin J, Loch S, Hobohm K, Funke J, Wieneke R, Koch J, Skach WR, Mayerhofer PU, Tampé R.

J Biol Chem. 2011 Dec 2;286(48):41402-12. doi: 10.1074/jbc.M111.237784. Epub 2011 Oct 7.

6.

Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.

Horst D, Burrows SR, Gatherer D, van Wilgenburg B, Bell MJ, Boer IG, Ressing ME, Wiertz EJ.

J Virol. 2012 Jan;86(1):572-7. doi: 10.1128/JVI.05151-11. Epub 2011 Oct 19.

7.

The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.

Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R.

PLoS Pathog. 2012;8(5):e1002704. doi: 10.1371/journal.ppat.1002704. Epub 2012 May 17.

8.

Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.

Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ.

Semin Cancer Biol. 2008 Dec;18(6):397-408. doi: 10.1016/j.semcancer.2008.10.008. Epub 2008 Oct 25. Review.

PMID:
18977445
9.

Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.

Strong MJ, Laskow T, Nakhoul H, Blanchard E, Liu Y, Wang X, Baddoo M, Lin Z, Yin Q, Flemington EK.

J Virol. 2015 Oct;89(19):10110-4. doi: 10.1128/JVI.01110-15. Epub 2015 Jul 15.

10.

Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.

Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR, et al.

Eur J Immunol. 1995 May;25(5):1374-84.

PMID:
7774641
11.

Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.

Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, Hislop AD, Rowe M.

PLoS Pathog. 2014 Aug 21;10(8):e1004322. doi: 10.1371/journal.ppat.1004322. eCollection 2014 Aug.

12.

Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses.

Verweij MC, Ressing ME, Knetsch W, Quinten E, Halenius A, van Bel N, Hengel H, Drijfhout JW, van Hall T, Wiertz EJ.

Mol Immunol. 2011 Mar;48(6-7):835-45. doi: 10.1016/j.molimm.2010.12.008. Epub 2011 Feb 2.

13.

The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells.

Gram AM, Oosenbrug T, Lindenbergh MF, Büll C, Comvalius A, Dickson KJ, Wiegant J, Vrolijk H, Lebbink RJ, Wolterbeek R, Adema GJ, Griffioen M, Heemskerk MH, Tscharke DC, Hutt-Fletcher LM, Wiertz EJ, Hoeben RC, Ressing ME.

PLoS Pathog. 2016 Apr 14;12(4):e1005550. doi: 10.1371/journal.ppat.1005550. eCollection 2016 Apr.

15.

A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.

Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D, Croft NP, Neefjes JJ, Rickinson AB, Wiertz EJ.

J Exp Med. 2007 Aug 6;204(8):1863-73. Epub 2007 Jul 9.

16.
18.
20.

Supplemental Content

Support Center